ATB-340

ATB-340 is an experimental hydrogen sulfide (H2S)-releasing derivative of acetylsalicylic acid (aspirin) designed to retain cyclooxygenase (COX) inhibitory and antiplatelet/anti-inflammatory effects while markedly reducing gastrointestinal (GI) toxicity. Preclinical studies in rat models of chronic gastric ulcer show that ATB-340 maintains systemic and gastric COX inhibition and suppression of prostaglandin E2 yet does not delay or impair ulcer healing, in contrast to equimolar aspirin, and instead enhances anti-inflammatory and anti-oxidative responses at the ulcer margin.[5] ATB-340 has also been shown to reduce oxidative stress and improve gastric mucosal defense in aged, hyperglycemic or stress-exposed rats, associated with increased activities of H2S-related enzymes (cystathionine β-synthase, cystathionine γ-lyase, and thiosulfate sulfurtransferase), supporting its development as a GI-safer aspirin analogue.[2][5][6] It has been developed within Antibe Therapeutics’ H2S-NSAID platform as a potential GI-safe antiplatelet/analgesic agent.[1][3][7][13][14]